Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance

October 26, 2017 4:30 PM EDT

Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $135.3 million versus the consensus estimate of $112.81 million.

2017 Financial Outlook

Seattle Genetics updated its full year 2017 financial guidance as follows:

Current Previous
Revenues from collaboration and license agreements $90 million to $100 million $75 million to $90 million
Royalty revenues $60 million to $65 million $50 million to $55 million
Research and development expenses $460 million to $480 million $460 million to $500 million

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here
.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings